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PENYARINGAN MAYA BERDAYA TINGGI BAGI PERENCAT 
NEURAMINIDASE SELESEMA BURUNG (H5Nl) 
ABSTRAK 
HSNI adalah satu daripada sub-jenis Vlrus influenza yang boleh 
menyebabkan ancaman pandemik bukan sahaja kepada burung, tetapi juga kepada 
kebanyakan spesis lain tennasuk manusia. Neuraminise Nt adalah enzim 
glikoprotein yang terdapat di pennukaan partikel virus influenza. Di dalam kajian ini, 
penyaringan maya berdaya tinggi dijalankan bagi mengenalpasti molekul kimia yang 
dapat menyahaktifkan fungsi neuraminidase Nt. Dengan menggunakan struktur 
molekul kimia daripada pangkalan data NADI-CHEM, sejumlah 2498 struktur 
molekul kimia yang boleh diabstrak daripada tumbuhan semulajadi di Malaysia 
didokkan kepada enam konfonnasi neuraminidase Nt yang berbeza menggunakan 
perisian AutoDock 3.0.5. Enam konfonnasi neuraminidase yang berbeza diperolehi 
dengan melakukan simulasi dinamik molekul terhadap struktur monomer dan 
tetramer neuraminidase. Keputusan yang diperolehi disusun mengikut tenaga bebas 
pengikatan terendah (BFE). Basi proses penyaringan yang dilakukan terhadap 
konformasi-konformasi monomer neuraminidase, lima ligan menduduki kedudukan 
100 teratas tenaga bebas pengikatan terendah. Ligan-ligan tersebut adalah drlmene, 
faradiol, ocbrolifuanine ~ beta-amyrin dan cycloartenol. Bagi proses penyaringan 
yang dilakukan kepada konfonnasi-konfonnasi tetramer neuraminidase, empat ligan 
iaitu drlmene, ochrolifuanine A, asid jacoumarlk dan asid iftlaionik menduduki 
kedudukan 100 teratas tenaga bebas pengikatan terendah. Kesemua ligan yang dipilih 
mempunyai tenaga bebas pengikatan yang lebih rendah daripada oseltamivir (-9.36 
kcallmol). Lima ligan iaitu, drimene, faradiol, heta-amyrin, ocbrolifuanme ~ dan 
asid iftlaionik mengikat kepada konfonnasi-konformasi monomer dan tetramer 
xv 
dengan bacaan Ki antara 0.1 nM dan 10 nM. Semua ligan yang dianalisa tersebut 
berada pada kedudukan poket aktif neuraminidase. Malah, drimene dan 
ochrolifuanine A berupaya untuk mengikat pada konfonnasi kawasan aktif '150-
loop' 'terbuka' dan 'I 50-loop , 'tertutup' dengan tenaga bebas pengikatan yang lebih 
rendah berbanding tenaga bebas pengikatan oseltamivir. Daripada analisa mendalam 
yang dijalankan didapati semua ligan tersebut mempunyai potensi untuk dijadikan 
sebagai penghalang fungsi neuraminidase. 
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VIRTUAL HIGH THROUGHPUT SCREENING FOR AVIAN INFLUENZA 
(H5Nl) NEURAMINIDASE INHIBITORS 
ABSTRACT 
Avian influenza HSNI virus which caused virulent influenza in birds is a 
pandemic threat causing viral disease in many species including humans. 
Neuraminidase Nt, an antigenic glycoprotein enzyme found on the surface of the" 
influenza particle, was chosen as a drug target for virtual high-throughput drug 
screening of small molecules that is capable of blocking its activity. A total of 2498 
compounds derived from Malaysian natural plants in NADI-CHEM Structure 
Database were docked to six different neuraminidase confonnations derived from 
molecular dynamics simulation of neuraminidase monomer and tetramer using 
AutoDock 3.0.5. The results were ranked according to the lowest binding free energy 
(BFE). From this screening process, five ligands exist in all top 100 BFE ranking in 
the molecular docking with different conformations of the neuraminidase monomer. 
The ligands were drimene, faradiol, ochrolifuanine A, beta-amyrin and cycloartenol. 
In molecular docking with different conformations of the neuraminidase tetramer, 
drimene and ochrolifuanine A in addition to jacoumaric acid and iftlaionic acid 
scored in too BFE ranking, and were chosen for detailed binding studies. 
Interestingly, all selected ligands from molecular docking with Nl monomer and 
tetramer conformations scored more favourable binding free energy compared to 
oseltamivir (-9.36 kcal/mol). Five ligands, namely drimene, faradiol, beta-amyrin, 
ochrolifuanine A, and iftlaionic acid bind to N 1 monomer and tetramer 
conformations with acceptable KJ values, ranging from 0.1 nM to 10 nM. All the 
selected ligands bind significantly to the neuraminidase binding pockets. Drimene 
XVII 
and ochrolifuanine A are capable of binding to both 'open' and 'closed' ISO-loop 
active site conformation with binding free energy better than oseltamivir. The results 
indicate that these ligands have potential to be explored as new neuraminidase 
inhibitor. 
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CHAPTER ONE 
INTRODUCTION 
The first highly pathogenic H5Nl virus case was detected on 1996, isolated 
from a farmed goose in Guangdong Province, China In 1997, similar outbreaks were 
- --
reported in poultry at farms and live animal markets in Hong Kong .. That same year, 
also witness the first human infections with avian influenza H5Nl case in Hong 
Kong. 18 cases (6 fatal) were reported in Hong Kong. Altogether, 18 cases (6 fatal) 
are reported in the first known instance of human infection with this virus (World 
Health Organization, 2008). 
After several years, in 2003, two human cases of avian influenza H5Nl 
infection (one fatal) are confirmed in a Hon~ Kon~ family. H5Nl infections on 
human then are reported in several Asian countries like Hong Kong, China, Vietnam, 
Thailand, Cambodia and Indonesia. In early 2006, the first case in Middle East is 
detected in Turkey. The viruses are similar to those currently circulating in birds but 
it rapidly end in the coming week. Other cases of H5Nl are reported in Iraq, 
Azerbaijan, and Egypt. On January 2007, Nigeria, a West Africa country, confirms 
its first human case (World Health Organization, 2008). Until now, the numbers of 
reported cases continue to increase and there are no signs to stop (poland et al., 
2001). 
From the increasing number of avian influenza cases from time to time and 
with the highly fatality, this pandemic should be stopped. Many researches and 
1 
phannaceutical company came with efforts to discover effective drugs to stop the 
pandemic (Kim et al., 1999, Babu et al., 2000, Du et al., 2007). 
At present there are four drugs available worldwide for avian flu treatment 
namely amantadine, rimantadine, oseltamivir, and zanamivir. However, none of the 
four drugs have been shown to effectively prevent serious influenza·related 
complications such as bacterial or viral pneumonia. In addition, reports proved that . 
in some cases the viruses were resistance to the drugs (Le et al., 2005, Gubareva, 
2004, McKimm-Breschkin, 2000, Wang et al., 2007). Studies have shown that all 
four drugs can reduce the duration of symptoms by one day only if taken within 2 
days of the onset of the illness. According to the report published by the National 
Institute of Health, these drugs generally cause side effects such as nausea, vomiting, 
wheezing or serious breathing problems, headache and diarrhea. Thus, there is a need 
for the discovery of a new drug to address this problem. With the availability of the 
structure of neuraminidase NI, a virtual high throughput screening (vHTS) program 
can be initiated (Fanning et al., 2000, Kim et al., 1991, Russell, et al., 2006, Wei et 
al., 2006, Wang et al., 2007). 
The cost of developing drug in the conventional manner is prohibitive with 
the advent of cheap computing power, we can use in silico high throughput drug 
screening techniques to identify new hit compound. Using this technique, the 
screening of potential ligands will be done using molecular docking simulation. A 
library of ligand. the NADI-CHEM database will be used for this purpose (Natural 
Based Drug Discovery Intelligent-Chemical Structure Database, 2007). 
2 
The objectives of this research are: 
1. To identitY hit compounds that have potential to inhibit neuraminidase Nt. 
The small chemical compounds that used in this study come from local 
natural products and will hopefully generate a high value hit compounds that 
can react directly to numerous comfonnations of neuraminidase Nl. 
2. To characterize the molecular interaction of the hit ligands. Small ligands 
which have significant interactions to neuraminidase N 1 will be identified 
and will be studied further as drug lead compounds. 
3 
CHAPTER TWO 
LITERATURE REVIEW 
2.1 Avian Influenza Virus 
2.1.1 Influenza virus classification 
; Group A influenza virus can be classified into a subtype on the basis of two 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA and NA are 
two surface glycoproteins on the surface of avian influenza virus. Altogether, there 
are sixteen subtypes of hemagglutinin and nine subtypes of neuraminidase (Chen, et 
al.,2007). 
This fonnation of various subtypes for avian influenza A is caused by 
phenomenon called antigenic drift and antigenic shift. Antigenic drift happens all the 
time, but antigenic shift happens only occasionally. Antigenic drift happens when 
point of mutations or gradual genetic change occurring in the two known genes that 
contain the genetic material to produce glycoproteins, HA and NA. Antigenic drift 
produces new virus strains that may not be recognized by antibodies. Further, it may 
lead to loss of immunity. This type of antigenic drift occurs in all types of influenza 
group A, B, and C (Carrat and Flahault, 2007; Itzstein, 2007). 
Antigenic shift refers to an abrupt change in HA and NA combination to 
produce new influenza A virus subtype. It happens through a process called genetic 
4 
= 
reassortment. During the rearrangement, strains are enabled to jump from one species 
to another. 
Two different strains of influenza A can combine and form a new subtype. A 
new global pandemic may occur if a new subtype of influenza A virus is introduced 
into human population. Antigenic shift can occur in three ways; (a) from wild 
waterfowl to humans through genetic change in an intennediate host such as chicken 
or pig, and a human virus infects the intermediate host at the same time 
(reassortment); (b) directly from waterfowl to humans without genetic change; or (c) 
from waterfowl to an intennediate host without genetic change (Figure 2.1) 
(Goldrick, 2007). Thus far, antigenic shift has been reported to occur only in 
influenza group A. 
Influenza viruses required host cells to supply viral enzymes in their 
replication process. This was first suggested more than 25 years ago, when it was 
shown that influenza A virus required a functioning nucleus in which to replicate, in 
contrast to other RNA viruses that replicate in the cytoplasm of their host cells 
(Voyles, 2002). 
Both HA and NA are involved in avian influenza replication process. HA is 
involved in the attachment and fusion protein. HA binds to the terminal sialic acid on 
the viral receptor. HA then mediates the fusion of the virion and vesicle membrane 
process. Neuraminidase cleaves sialic acid linkages and releases the newly fonned 
progenies from the host cell. 
5 
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Figure 2.1 The process of avian influenza antigenic shift (Source: National Institute 
of Allergy and Infectious Diseases accessed on July 9, 2008) 
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2.1.2 Avian Influenza H5Nl 
Avian influenza or also known as bird flu is an infectious disease of birds and 
mammals caused by RNA virus (Figure 2.2). H5Nl virus is an influenza A virus that 
occurs mainly in birds, is highly contagious among birds, and can be deadly to them. 
To date, animal infected H5NI virus cases have been reported in seventy countries 
according to the World Health Organization (WHO, 2008). During late 2003 and, 
early 2004, H5Nl affected more than 100 million birds that either died from the 
disease or were killed in order to try to control the outbreaks. 
Chillingly, there have been reports of human fatilities caused by this virus. 
About 258 human infections (as of November 13, 2006). have been reported in 
Cambodia, China, Indonesia, Thailand, Turkey and Vietnam. H5Nl infection may 
follow an unusually aggressive clinical course, with rapid deterioration and high 
fatality. This is demonstrated in the current situation in Asia, where the mortality rate 
is approximately 50010. The impact of H5Nl pandemic is catastrophic as shown by 
the US congressional Budget Office that has estimated that up to 2 million of the US 
population might die, with up to 40% of all workers ill for as long as 3 or more 
weeks should the pandemic occur. Financially, this is translated into a ,total cost of 
US$683 billion covering the deaths, clinically ill, and outpatient treatment cost. 
Before the virus mutate into a form that infect human aggressively, it is necessary to 
develop drugs to stem the progression of isolated incidences into a full-blown 
epidemic (Levi, et aI., 2007). 
7 
Figure 2.2 Influenza A Virus (Source: International Committe on Taxonomy of 
Viruses accessed on March 8, 2011) 
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2.1.3 Pathogenicity 
Further classification of the avian influenza virus is according to the basis of 
specific molecular genetics and pathogenesis criteria that need specific testing. Low 
pathogenic (LP AI) virus is usually associated with mild disease in poultry and high 
pathogenic (HP AI) virus refers to the strain causing severe illness and high mortality 
in poultry. The "North American H5Nl is referred to as the Low Pathogenic H5Nl" 
whereas the "Asian" HSNl is known as the High pathogenic H5Nl because of its 
high rates of mortality and causing worldwide concern (Spackman, et aI., 2007). 
From 2003 to 2006, high pathogenic A (H5NI) influenza viruses have had a 
devastating impact on domestic or wild birds in many parts of South East Asia, 
Europe, the Middle East and Africa. The HP AI subtype A (HSNl) has been the cause 
of large scale death in poultry and the subsequent infection and death of over 140 
humans (Hurt, et al., 2007). While the virus is not easily transmitted from human to 
human, there might be further mutation or genetic reassortment that can produce a 
strain which has the potential to cause a pandemic. 
2.1.4 Avian iDOuenza viral proteiD 
Influenza virus is an orthomyxovirus and the structure is well known (Figure 
2.3). Avian influenza A virus is an enveloped virus. It contains of eight segments of 
negative sense single stranded RNA that encode 11 proteins. These proteins are 
polymerase-7mO CAP binding, polymerase-elongation, polymerase, hemagglutinin, 
9 
NA (Neuraminidase) 
Figure 2.3 Schematic structure of influenza virus (Source: International Federation 
of Phannaceutical Manufacturers & Associations accessed on January 24, 2008) 
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nucleoprotein, neuraminidase, matrix proteins, and non-structural proteins (Chen, et 
al., 2006). Table 2.1 presents the gene assignments in influenza A virus (Voyles, 
2002). The nucleocapsids of the virus are helical. This virus is a pleomorphic virus, 
meaning its shape varies. The lipid envelope contains the M2 ion channel protein and 
the viral glycoproteins, hemagglutinin and neuraminidase. Within the envelope, the 
HA and NA proteins are relatively abundant, whereas the M2 protein is present in 
relatively few copies (Basler, 2007). 
Beneath the viral membrane is the viral matrix protein, Ml. The 
nucleoprotein (NP) associates with the eight genomic RNA segments to form the 
ribonucleoprotein complexes (RNPs) lie inside the virus. United with this structure is 
the viral polymerase; PA, PB 1 and PB2, and also viral nuclear export protein (NS2). 
2.1.5 Avian influenza replication process 
The replication process of this orthomyxovirus differs from other type of 
viruses. The genome is transcribed to mRNAs and replicated to form new genomes. 
Influenza viruses bind through hemagglutinin onto sialic acid sugars on the surfaces . 
of epithelial cells (Itzstein, 2007; Oxfo~ 2000; Skehel and Wiley, 2000). The virus 
enters the host cell by endocytosis, and further appears in endosome. Following 
endocytosis of the viral particle, the endosome undergoes acidification (Basler, 2007; 
DeTulleo and Kirchhausen, 1998; Yamashiro and Maxfiel~ 2004). Because of the 
acidic environment in the endosome, modification at the hemagglutinin spikes 
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Table 2.1 Gene assignments for influenza A virus segments 
Segment Number Protein Name Fundion 
I PB2 Polymerase-7mG CAP binding 
2 PBI Polymerase elongation 
3 PA Polymerase 
4 HA Hemagglutinin 
5 NP Nucleoprotein 
6 NA Neuraminidase 
7 Ml,M2 Matrix (membrane) proteins 
8 NSl, NS2 Non-structural proteins 
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happened, creating a hole, and the influenza virus releases viral RNA (vRNA) 
molecules, viral proteins and RNA-dependent RNA transcriptase into the cytoplasm. 
vRNA and proteins are then transported into host cell nucleus via the nuclear pores. 
Three virus polymerase proteins are involved in the both transcription and translation 
process, namely PB 1, PB2, and P A. The vRNA produces various kinds of viral 
messenger RNAs (vmRNA) which travel out through the nuclear pores. The vmRNA 
carries genetic infonnation that is used in manufacture of protein. 
Some of the newly synthesized vmRNAs have roles in the synthesis of 
nucleoprotein that travels back into the nucleus. Other vmRNAs direct the 
production of viral proteins and transmembrane viral proteins. Other viral proteins 
have multiple actions in the host cell, including degrading cellular mRNA and using 
the released nucleotides for vRNA synthesis and inhibiting the translation of host-
cellmRNAs. 
In the nucleus, the negative sense vRNA produces full-length positive sense 
copies of itself. This process is catalyzed by RNA-dependent RNA transcriptase. 
These are then used to create further copies of the negative sense vRNA. These new 
negative sense vRNAs become associated with nucleoproteins and some viral 
proteins that have migrated into the nucleus. Such newly fonned nucleocapsids and 
their associated M proteins exit the nucleus via nuclear pores. Around the new 
nucleocapsid, the viral proteins are collected beneath the cell membrane, while above 
the cell membrane; hemagglutinin and neuraminidase have coated the host cell 
surface (Skehel and Wiley, 2000). 
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With all these viral elements now in place, the newly fonned particles can 
begin to take shape and to bud from the cell surface. The cell membrane that 
envelopes the emerging nucleocapsid and matrix protein becomes the viral envelope 
(complete with projecting spikes) and the virus particle is then released once 
neuraminidase cleaved the sialic acid residues from host cells (Fanning, et aI., 2000). 
After the release of the new progeny influenza viruses, the host cell dies. 
2.1.6 Int1uenza virus inhibitors 
At this moment, vaccination is the important way for preventing avian flu. 
But, in some condition, vaccination is inadequate and effective antiviral agents 
would be of the utmost importance. Antigenic drift of influenza virus may occur 
between any influenza pandemic seasons. This will cause the currently available 
vaccine to be less protective. Furthennore, once a pandemic occurs, the production of 
influenza vaccine cannot accommodate the needs of the population. Therefore, 
antiviral still playa major role as a treatment of influenza infection. 
There are several known anti-influenza inhibitors nowadays (Figure 2.4) 
(Clark. 2004; Clercq and Neyts. 2007). Amantadine and rimantadine are known as 
M2 channel inhibitors. IMP dehydrogenase inhibitors like ribavarin and viramidine 
can be used to block the RNA replication and transcription steps which require 
repeated cycles of (-)RNA .... (+ )RNA polymerization reactions occur in the 
nucleus (Clercq and Neyts, 2007). While, neuraminidase as a glycoprotein enzyme is 
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inhibited by oseltamivir, zanamivir and peramivir (Boltz, et al., 2007; Gubareva, 
2004; Hayden, 2001; Kim, et al., 1999; Leneva, et al., 2000; Sun, et al., 2006; Wei, et 
aI.,2006). 
The experimental inhibition parameters for known inhibitors of influenza 
virus neuraminidase are shown in Table 2.2 (Taylor, 2003). Sialic acid is a weak 
inhibitor for neuraminidase with a Kt value of ImM. F ANA was the best inhibitor of 
neuraminidase for some years with a K; = 0.8 JlM (Taylor, 2003). The most effective 
inhibitors that have been developed are oseltamivir and zanamivir with Ki values 
lower than 1.3 nM (Taylor, 2003). 
However, there are many weaknesses of the inhibitors reported. None of the 
inhibitors for M2 channel ion and neuraminidase have been shown to effectively 
prevent serious influenza-related complications such as bacterial or viral pneumonia. 
Studies have shown that some of the drugs can reduce the duration of flu symptoms 
by 1 day only if taken within 2 days of the onset of the illness (Smith, et al., 1980). 
According to the report published by National Institute of Health, these drugs 
generally, cause fewer side effects. In some cases, oseltamivir caused nausea and 
vomiting. The common side effects of zanamivir are wheezing or serious breathing 
problems, headache and diarrhea (National Institute of Health, 2008). 
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enza virus Table 2.2 Inhibition parameters for known inhibitors of influ 
neuraminidase 
lntluenza A virus 
Inhibitors 
Ki ICso 
Sialic acid ImM 
-
DANA 4 JIM 0.015 mM 
FANA 0.8 JIM -
Zanamivir 0.06-1.3 nM 0.3-2.3 nM 
Oseltamivir 0.10-1.3 nM 0.01-2.2 nM 
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2.2 Neuraminidase as a Drug Target 
There are many ways to inhibit influenza virus function. M2 ion channel, 
IMP dehydrogenase, RNA polymerase, hemagglutinin and neuraminidase were 
known as anti-viral targets. One of the most chosen targets among researches is 
neuraminidase (Fanning, et al., 2000; Hayden, 2001; Kim, et al., 1997). 
Neuraminidase has been chosen as a drug target because it has a broader 
antiviral spectrum, better tolerance, less potential for emergence of resistance, close 
correspondence of the conserved residues of the active site from all influenza 
neuraminidases, and in vitro studies demonstrated both HA and NA susceptibility to 
NA inhibitors (Zhang and Xu, 2006). Besides, the existing inhibitors, such as 
oseltamivir and zanamivir, were developed based on different structures of 
neuraminidase (Du, et al., 2007). 
2.2.1 The neuraminidase active site 
Neuraminidase can be categorized into two groups structurally; group-1 
includes N1, N4, N5, and N8 and group-2 includes N2, N3, N6, N7. and N9 
(Landon, et al., 2008). The active site for N1 and all group-1 neuraminidases is 
different from group-2 especially at the 150-loop (residues 147-Arg152) region. The 
conformation of the ISO-loop is such that the en position of the group-1 specific 
Val149 is about 7A distant from the equivalent isoleucine residue in group-2. The 
hydrophobic side chain at Val149 is pointed away from the active site. There is a 
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large cavity adjacent in NI active site region. The ISO-cavity is about 10 A long and 
5 A wide and deep (Russell, et aI., 2006). 
In vitro, NI can bind with an inhibitor in either the 'open' or 'closed' 
conformation of the ISO-loop, depending on the soaking conditions. Incubating Nt 
crystals in 20 J.IM oseltamivir for 150 minutes showed binding of the inhibitor with 
the ISO-loop in the open cavity confonnation (Collins, et aI., 2008; Russell, et a1.; 
2006). While, at a higher concentration of inhibitor, the ISO-loop changes its 
conformation to close-cavity conformation. The main change in the conformation is 
the Glu 119 and Asp 151 residues are now oriented facing the bound inhibitor to form 
a 'closed' conformation. 
This ISO-loop'S motion is coupled to the motion of the neighbouring 430-
loop. The 430-loop comprises residues Arg43 0-Thr439. The 430-loop helps to 
expand the active site's cavity. These coupled motions significantly expanded the 
active site cavity, increasing its solvent-accessible surface area as compared with 
both open and closed crystal structures (Amaro, et aI., 2007; Lando~ et aI., 2008). 
A study showed that for both the apo and holo molecular dynamic 
simulations of neuraminidase, the greatest structural diversity is found in the IS0-
loop and 430-100p areas, aIthough the entire binding-site region was used in the 
clustering. This indicates that the ISO-loop and 430-loop areas are particularly 
flexible (Landon, et aI., 2008). The two most variable regions in the binding site are 
highlighted in Figure 2.5. 
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Figure 2.5 The location of ISO-loop and 430-loop region in neuraminidase 2HU4. 
(Landon et aI., 2008) 
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The neuraminidase active site can be divided into three major binding pockets 
as shown in Figure 2.6 (Lew, et aI., 2000). The polar residues in the Nl active site 
Glu276, Glu277, Arg292, Asn294, and hydrophobic Ala246 make up Pocket 1. 
Pocket 2 consists of the highly conserved amino acids residues Ile222, Arg224, and 
Ala246. The third binding pocket is the largest and is made up from hydrophobic and 
hydrophilic residues; Glu119, Asp151, Arg152, Trp178, SerI79, Ile222, and Glu227 
(Lew, et al., 2000; Wang, et al., 2007). 
2.2.2 3-Dimentional structure of neuraminidase 
The first step in running a screening process is to get a suitable protein as a 
target. The ideal receptor is one that is closely linked to human disease and binds a 
small molecule in order to carry out a function. The target receptor should have a 
well-defined binding pocket. Other designed small molecule can compete with the 
natural small molecule in order to modulate the function of the receptor at a required 
level of potency. The receptor should be essential and its elimination should lead to 
the pathogen's death. Finally, the target receptor should be able to be inhibited by 
binding a small molecule. 
Crystal structures are the most common source of structural information for 
drug design. A crystal structure should be evaluated for the resolution· of the 
diffracted amplitudes or often simply called resolution, reliability or R factors, 
coordinate error, temperature factors and chemical correctness. Typically, crystal 
structures determined with data extending to beyond 2.5 A are acceptable for drug 
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Figure 2.6 Three major binding pockets of neuraminidase active site. 
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design purposes since they have a high data to parameter ratio, and the placement of 
residues in the electro~density map is unambiguous (Anderson, 2003). The Rfree 
should be below 28% and R factor should be well below 25%. Coordinate error in 
Protein Data Bank is calculated using Luzzati method and should be in the range of 
0.2 A - 0.3 A. Temperature factors of atoms in the region of interest should be no 
greater than the average temperature factor for the molecule. Finally, the molecule 
should be reftned to be consistent with all rules of stereochemical "correctness". 
After a careful observation in the Brookhaven Protein Data Bank, the Nl in complex 
with oseltamivir (PDB code: 2hu4) was chosen as a drug target (Figure 2.7). It was 
found in 2006 through x~ray diffraction. The neuraminidase structure contains eight 
chains with 388 residues each. 
The chosen X-ray crystal structure of neuraminidase Nl contains eight 
chains; they are chain A, B, C, D, E, F, and G. All of them are similar in term of the 
size and amino acids sequences. Thus, it is sufficient for the purpose of this study to 
select one chain. The weight of the protein is 42,111.6 with 385 amino acid residues 
(Figure 2.8). 
2.3 Introduction to Drug Discovery and Molecular Modelling 
Drug discovery and development is an expensive process due to the high 
research and development costs and extensive clinical test. A study in year 2003 
23 
Figure 2.7 Crystal structure of neuraminidase Nt (2HU4) 
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